Dacetuzumab is used for its anti-lymphoma activity; it induces apoptosis in myeloma cells in vitro and demonstrates potent anti-tumor effects in combination with other monoclonal antibodies in vivo; it is currently in Phase I clinical trials for the treatment of multiple myeloma (MM).